APOC-III-directed RNA Interaction Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: APOC-III-directed RNA Interaction
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 11,174,481 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 12,365,899 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 11,214,801 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 10,597,657 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 10,294,474 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
